Display options
Cite
Kobawala TP, Trivedi TI, Gajjar KK, et al. Significance of Interleukin-6 in Papillary Thyroid Carcinoma. J Thyroid Res. 2016;2016:6178921doi: 10.1155/2016/6178921.
Kobawala, T. P., Trivedi, T. I., Gajjar, K. K., Patel, D. H., Patel, G. H., & Ghosh, N. R. (2016). Significance of Interleukin-6 in Papillary Thyroid Carcinoma. Journal of thyroid research, 20166178921. https://doi.org/10.1155/2016/6178921
Kobawala, Toral P, et al. "Significance of Interleukin-6 in Papillary Thyroid Carcinoma." Journal of thyroid research vol. 2016 (2016): 6178921. doi: https://doi.org/10.1155/2016/6178921
Kobawala TP, Trivedi TI, Gajjar KK, Patel DH, Patel GH, Ghosh NR. Significance of Interleukin-6 in Papillary Thyroid Carcinoma. J Thyroid Res. 2016;2016:6178921. doi: 10.1155/2016/6178921. Epub 2016 Mar 13. PMID: 27034885; PMCID: PMC4808558.
Copy Download .nbib Format: NLM
Share it on

J Thyroid Res. 2016;2016:6178921. doi: 10.1155/2016/6178921. Epub 2016 Mar 13.

Significance of Interleukin-6 in Papillary Thyroid Carcinoma.

Journal of thyroid research

Toral P Kobawala, Trupti I Trivedi, Kinjal K Gajjar, Darshita H Patel, Girish H Patel, Nandita R Ghosh

Affiliations

  1. Division of Molecular Endocrinology, Cancer Biology Department, The Gujarat Cancer & Research Institute, NCH Compound, Asarwa, Ahmedabad, Gujarat 380016, India.

PMID: 27034885 PMCID: PMC4808558 DOI: 10.1155/2016/6178921

Abstract

This study sought to reveal the significance of IL-6 in papillary thyroid carcinoma by determining its circulating levels, tumoral protein, and mRNA expressions. As compared to the healthy individuals, serum IL-6 was significantly higher in patients with benign thyroid diseases and PTC. Further, its level was significantly higher in PTC patients as compared to patients with benign thyroid diseases. ROC curves also confirmed a good discriminatory efficacy of serum IL-6 between healthy individuals and patients with benign thyroid diseases and PTC. The circulating IL-6 was significantly associated with poor overall survival in PTC patients. IL-6 immunoreactivity was significantly high in PTC patients as compared to the benign thyroid disease patients. Significantly higher IL-6 mRNA expression was also observed in the primary tumour tissues of PTC patients than the adjacent normal tissues. The protein expression of IL-6 at both the circulating and tissue level correlated with disease aggressiveness in PTC patients. Moreover, a significant positive correlation was observed between the IL-6 protein and mRNA expression in the primary tumours of PTC patients. Finally in conclusion, IL-6 has an important role in thyroid cancer progression. Thus targeting IL-6 signalling can help in clinical management of thyroid carcinoma patients.

References

  1. Cancer. 2002 Sep 1;95(5):1071-5 - PubMed
  2. Cancer Treat Rev. 2012 Nov;38(7):904-10 - PubMed
  3. Am J Physiol Cell Physiol. 2005 Oct;289(4):C971-81 - PubMed
  4. Int J Mol Sci. 2014 Dec 24;16(1):159-77 - PubMed
  5. Int J Oncol. 2014 May;44(5):1551-60 - PubMed
  6. Oncol Rep. 2013 Jan;29(1):34-8 - PubMed
  7. J Endocrinol Invest. 2002 Dec;25(11):959-66 - PubMed
  8. Cancer Cell. 2009 Feb 3;15(2):103-13 - PubMed
  9. Int J Oncol. 2012 Jul;41(1):310-6 - PubMed
  10. Psychosomatics. 2008 Jan-Feb;49(1):64-6 - PubMed
  11. Tumour Biol. 2005 Jul-Aug;26(4):186-94 - PubMed
  12. Breast Cancer Res Treat. 2013 Apr;138(3):657-64 - PubMed
  13. Int J Oncol. 2012 Apr;40(4):1171-9 - PubMed
  14. Clin Cancer Res. 2003 Oct 15;9(13):4653-65 - PubMed
  15. Clin Breast Cancer. 2015 Feb;15(1):e13-21 - PubMed
  16. OMICS. 2011 Mar;15(3):183-6 - PubMed
  17. Br J Cancer. 2013 Jul 9;109(1):131-7 - PubMed
  18. Br J Cancer. 2013 May 28;108(10):2063-9 - PubMed
  19. J Clin Invest. 2007 Dec;117(12 ):3660-3 - PubMed
  20. World J Gastroenterol. 2005 Mar 21;11(11):1639-43 - PubMed
  21. Neoplasma. 2014;61(2):205-12 - PubMed
  22. Oncology. 2013;84(6):356-61 - PubMed
  23. BMC Cancer. 2012 Sep 21;12:418 - PubMed
  24. Gastroenterology. 2005 Jun;128(7):2054-65 - PubMed
  25. Annu Rev Immunol. 2005;23:1-21 - PubMed
  26. Int J Cancer. 2009 Jun 15;124(12):2766-70 - PubMed
  27. PLoS One. 2013 Jun 26;8(6):e67059 - PubMed
  28. Cancer Manag Res. 2011;3:177-89 - PubMed
  29. Chirurgia (Bucur). 2012 Jan-Feb;107(1):59-65 - PubMed
  30. Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1214-24 - PubMed
  31. Pathologe. 1987 May;8(3):138-40 - PubMed
  32. Scand J Urol. 2015 Apr;49(2):120-6 - PubMed
  33. Br J Cancer. 2004 Dec 13;91(12):1993-5 - PubMed
  34. Int J Surg. 2012;10(10):638-40 - PubMed
  35. Clin Cancer Res. 1998 Feb;4(2):381-7 - PubMed
  36. PLoS One. 2014 May 21;9(5):e97613 - PubMed
  37. Clin Cancer Res. 2011 Sep 15;17(18):6083-96 - PubMed
  38. Int Immunol. 2010 May;22(5):347-52 - PubMed
  39. Gastric Cancer. 2005;8(2):124-31 - PubMed
  40. Endocr Relat Cancer. 2010 Feb 18;17(1):241-53 - PubMed
  41. Cancer Sci. 2014 Sep;105(9):1220-7 - PubMed
  42. J Clin Endocrinol Metab. 1994 Nov;79(5):1424-7 - PubMed
  43. Oncogene. 2007 May 3;26(20):2822-32 - PubMed
  44. Int J Cancer. 2007 Jun 15;120(12):2600-8 - PubMed
  45. Oncol Rep. 2015 May;33(5):2161-8 - PubMed
  46. Clin Cancer Res. 2011 Apr 15;17 (8):2538-48 - PubMed
  47. Rom J Morphol Embryol. 2011;52(4):1261-7 - PubMed
  48. Clin Cancer Res. 2000 Jul;6(7):2702-6 - PubMed
  49. Biochem Biophys Res Commun. 2013 May 31;435(2):188-94 - PubMed
  50. World J Surg Oncol. 2015 Mar 28;13:129 - PubMed
  51. Ulus Cerrahi Derg. 2013 Mar 01;29(1):7-10 - PubMed
  52. Jpn J Clin Oncol. 2010 Jun;40(6):580-7 - PubMed
  53. PLoS One. 2015 Feb 06;10(2):e0118080 - PubMed
  54. Eur J Cancer. 2003 Jan;39(2):184-91 - PubMed
  55. Arch Immunol Ther Exp (Warsz). 2009 Jul-Aug;57(4):291-4 - PubMed
  56. Anticancer Res. 2006 Sep-Oct;26(5B):3905-11 - PubMed
  57. PLoS One. 2013 Oct 07;8(10):e75788 - PubMed
  58. Int J Colorectal Dis. 2010 Feb;25(2):135-40 - PubMed
  59. Expert Opin Biol Ther. 2005 May;5(5):683-90 - PubMed
  60. Cancer Genomics Proteomics. 2010 Nov-Dec;7(6):287-302 - PubMed
  61. Br J Cancer. 2014 Jan 21;110(2):469-78 - PubMed
  62. Anal Biochem. 1987 Apr;162(1):156-9 - PubMed
  63. Cancer Lett. 2006 Nov 28;244(1):76-8 - PubMed
  64. Int J Cancer. 2014 Aug 1;135(3):551-62 - PubMed
  65. J Physiol Biochem. 2004 Dec;60(4):253-8 - PubMed
  66. World J Surg Oncol. 2011 Feb 06;9:18 - PubMed
  67. Inflamm Res. 2014 Aug;63(8):667-74 - PubMed
  68. Int J Cancer. 2003 Feb 20;103(5):642-6 - PubMed
  69. Clin Biochem. 2007 Dec;40(18):1353-60 - PubMed
  70. Egypt J Immunol. 2006;13(2):61-8 - PubMed
  71. Indian J Clin Biochem. 2013 Jan;28(1):90-4 - PubMed
  72. PLoS One. 2012;7(11):e50104 - PubMed
  73. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Nov;29(11):1181-4 - PubMed
  74. J Clin Pathol. 2000 May;53(5):388-90 - PubMed
  75. Eur J Cancer. 2010 May;46(7):1223-31 - PubMed
  76. J Thyroid Res. 2016;2016:8143695 - PubMed
  77. Mol Cancer. 2013 Apr 05;12:26 - PubMed
  78. J Endocrinol Invest. 2009 Jun;32(6):491-4 - PubMed

Publication Types